| 2026-08-06 | Deck | Designing Proteins Delivering Medicines Corporate Overview August 2026 |
| 2026-08-05 | Press release | Xencor Reports Second Quarter 2026 Financial Results |
| 2026-08-05 | Press release | Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-29 | Press release | Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter |
| 2026-07-29 | Press release | Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter |
| 2026-07-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-17 | Press release | Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma |
| 2026-07-17 | Press release | Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma |
| 2026-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-06 | Press release | Xencor Reports First Quarter 2026 Financial Results |
| 2026-05-06 | Press release | Xencor Reports First Quarter 2026 Financial Results -- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26 start -- -- Plamotamab and XmAb657 autoimmune studies on-track for 2H26 progress update -- |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Document | XmAb942, a Novel Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease: Phase 1 Final Results |
| 2026-05-05 | Deck | Designing Proteins Delivering Medicines Results from Phase 1 Study of XmAb942 & TL1A Pipeline Update |
| 2026-05-05 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-04 | Press release | Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW |
| 2026-05-04 | Press release | Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW |
| 2026-04-27 | Document | Discovery and Characterization of XmAb412: A Novel, High-Affinity, Anti-TL1A x Anti- IL23(p19) Native-Like Bispecific Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease |
| 2026-04-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-27 | Proxy | Definitive proxy statement |
| 2026-03-09 | 8-K | Form 8-K, Item 1.02 |
| 2026-03-04 | Press release | Xencor Announces Change to Ultomiris® Royalty Revenue Forecast |
| 2026-03-04 | Press release | Xencor Announces Change to Ultomiris® Royalty Revenue Forecast |
| 2026-03-04 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-25 | Press release | Xencor Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-25 | Press release | Xencor Reports Fourth Quarter and Full Year 2025 Financial Results -- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose in ccRCC in 2H26 -- -- Final results from healthy-volunteer study of Xmb942, Xtend™ TL1A antibody, and preclinical characterization of XmAb412, TL1A x IL23p19 XmAb® bispecific antibody, to be presented at DDW 2026 |
| 2026-02-25 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-25 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-23 | Press release | Xencor to Participate at Upcoming Investor Conferences |
| 2026-02-23 | Press release | Xencor to Participate at Upcoming Investor Conferences |
| 2026-01-08 | Press release | Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones |
| 2026-01-08 | Press release | Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones |
| 2026-01-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-30 | Document | Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) |
| 2025-10-24 | 8-K | Form 8-K, Item 7.01 |